KRAS GENE MUTATION
Clinical trials for KRAS GENE MUTATION explained in plain language.
Never miss a new study
Get alerted when new KRAS GENE MUTATION trials appear
Sign up with your email to follow new studies for KRAS GENE MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Early trial tests drug cocktails to target advanced cancers
Disease control OngoingThis early-stage study is testing the safety and best doses of a drug called neratinib when given with one of three other drugs (everolimus, palbociclib, or trametinib). It is for adults with advanced solid tumors that have specific genetic mutations and have stopped responding t…
Matched conditions: KRAS GENE MUTATION
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New drug duo targets Tough-to-Treat lung cancer mutation
Disease control OngoingThis study is testing whether combining two drugs, trametinib and docetaxel, can help control advanced non-small cell lung cancer that has a specific genetic change called a KRAS mutation. It is for patients whose cancer has continued to grow despite one or two prior treatments. …
Matched conditions: KRAS GENE MUTATION
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
New hope for Tough-to-Treat lung cancer? experimental drug targets KRAS mutation
Disease control OngoingThis study is testing an experimental oral drug called TVB-2640 in people with advanced non-small cell lung cancer that has a specific genetic change called a KRAS mutation and has stopped responding to standard treatments. The main goals are to see if the drug can control the ca…
Matched conditions: KRAS GENE MUTATION
Phase: PHASE2 • Sponsor: David E Gerber • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New drug combo tested for Tough-to-Treat colorectal cancer
Disease control OngoingThis study is testing whether two drugs, panitumumab and trametinib, can help control advanced colorectal cancer that has stopped responding to a previous, similar type of treatment. It involves 59 patients whose cancer has spread and who have specific genetic markers in their bl…
Matched conditions: KRAS GENE MUTATION
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC